Analysed REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) News Sources
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
05-09-2026
yahoo.com
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval
05-09-2026
yahoo.com
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
10-09-2026
yahoo.com
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More.
10-09-2026
yahoo.com
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
12-09-2026
yahoo.com
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
14-09-2026
yahoo.com
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
16-09-2026
yahoo.com
What is the current price of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The current price of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is $10.46.
REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) absolute price change since previous trading day?
The absolute price change of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) since the previous trading day is $-0.84.
REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) percentage price change since previous trading day?
The percentage price change of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) since the previous trading day is -7.4336%.
What is the most recent average sentiment score for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The most recent average sentiment score for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The most recent sentiment for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is .
SEC-8K** Filing Available For REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.